Login

Consolidated balance sheets

In millions of USD, except per-share amounts
Q2 FY2026
As of Nov 30, 2025
Q1 FY2026
As of Aug 31, 2025
Q4 FY2025
As of May 31, 2025
Q3 FY2025
As of Feb 28, 2025
Q2 FY2023
As of Nov 30, 2022
Q1 FY2023
As of Aug 31, 2022
Q3 FY2022
As of Feb 28, 2022
Q1 FY2022
As of Aug 31, 2021
Q4 FY2022
As of May 31, 2022
Q1 FY2021
As of Aug 31, 2020
Q3 FY2020
As of Feb 29, 2020
Q4 FY2020
As of May 31, 2020
Q1 FY2020
As of Aug 31, 2019
Cash
Total current assets
Total assets
Accounts payable and accrued liabilities
Due to related party
Notes payable
Total current liabilities
Total liabilities
Common stock, $0.00001 par value, 500,000,000 shares authorized, 37,997,373 and 37,997,373 shares issued and outstanding as of November 30, 2025 and May 31, 2025 , respectively
Additional paid in capital
Stock payable
Accumulated deficit
Total stockholders' deficit
Total liabilities and stockholders' deficit
Series A Preferred stock, $0.00001 par value, 100,000,000 shares authorized, 5,850,000 and 5,850,000 shares issued and outstanding as of November 30, 2025 and May 31, 2025 , respectively
Series A Preferred Stock

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support